COVID-19 vaccines
COVID-19 vaccines

COVID-19 vaccines

WHO/N. K. Acquah
© Credits

Equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic, so it is hugely encouraging to see so many vaccines proving and going into development. WHO is working tirelessly with partners to develop, manufacture and deploy safe and effective vaccines. 

Safe and effective vaccines are a game-changing tool: but for the foreseeable future we must continue wearing masks, cleaning our hands, ensuring good ventilation indoors, physically distancing and avoiding crowds. 

Being vaccinated does not mean that we can throw caution to the wind and put ourselves and others at risk, particularly because research is still ongoing into how much vaccines protect not only against disease but also against infection and transmission.

See WHO’s landscape of COVID-19 vaccine candidates for the latest information on vaccines in clinical and pre-clinical development, generally updated twice a week. WHO’s COVID-19 dashboard, updated daily, also features the number of vaccine doses administered globally.

But it’s not vaccines that will stop the pandemic, it’s vaccination. We must ensure fair and equitable access to vaccines, and ensure every country receives them and can roll them out to protect their people, starting with the most vulnerable.

 

You can follow the status of COVID-19 Vaccines within WHO EUL/PQ evaluation process here.

Public Advice

COVAX and vaccine introduction

Regulation and policy

COVID-19 vaccines: what do we know

Latest vaccine news

All →

Multimedia

All →

Feature stories

All →

Other resources

Criteria for COVID-19 vaccine prioritization

The proposed attributes and criteria provide considerations for the evaluation and prioritization of COVID-19 candidate vaccines to be considered for further development by WHO. The target audience includes vaccine scientists, product developers, manufacturers, regulators and funding agencies.

Vaccine target product profile

WHO has published the target product profiles for COVID-19 vaccines, which describes the preferred and minimally acceptable profiles for human vaccines for long term protection of persons at high ongoing risk of COVID-19, and for reactive use in outbreak settings with rapid onset of immunity. We have also published the criteria for prioritization of vaccines for clinical trials.